{
    "2020-08-09": [
        [
            {
                "time": "2020-08-09",
                "original_text": "贝达药业：盐酸恩沙替尼EXalt3研究中期分析结果发布或成为公司第一个在全球上市的创新药",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盐酸恩沙替尼",
                        "EXalt3研究",
                        "中期分析结果",
                        "全球上市",
                        "创新药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}